Clonex Development

Clonex Development is a private biotechnology company focused on the discovery and development of therapeutic monoclonal antibodies and vaccines for infectious diseases and oncology. The company's lead program, CLX-155, is a human monoclonal antibody designed to neutralize the SARS-CoV-2 virus by targeting the spike protein. Clonex leverages a proprietary antibody discovery platform to identify high-affinity candidates with therapeutic potential. The company is closely affiliated with the Panorama Research Institute, a biotech incubator and research organization. Clonex aims to address high-need clinical areas by translating early-stage molecular research into viable clinical candidates.